Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

However, Pfizer decided not to pursue approval due to questions about its potential commercial performance. To address these challenges, the EMA launched a pilot programme in 2022 to support academic ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Gardasil has also been licensed in over 40 countries worldwide. Cervarix is awaiting European Medicines Agency (EMEA) approval, as well as that of the FDA. If their submission is 'fast-tracked ...

announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), combined with a standard-of-care regimen to treat adults with newly ...

Deal generates more cash for acquisitive French beauty group Sale price is a 2.8% discount to Sanofi’s Friday shares close. L’Oreal is selling 29.6 million shares at €101.50 each, the companies said ...

French fuel cell technology firm EODev (Energy Observer Developments) has received type approval from the classification society Bureau Veritas for its hydrogen fuel cell system. The certification was ...